ARCH Ventures

ARCH Venture Partners is a venture capital firm specializing in seed and early-stage investments in disruptive science and technology companies, primarily focused on biotechnology, life sciences, and healthcare innovations that prevent, detect, and cure diseases. The firm takes a contrarian approach, backing bold, high-risk technologies from groundbreaking scientific discoveries, often founding companies in partnership with leading researchers and institutions. With investments ranging from $50K to hundreds of millions per company, ARCH emphasizes long-term company building over quick exits, providing not just capital but strategic guidance, networks, and follow-on funding to scale transformative platforms in therapeutics, diagnostics, genomics, and related deep-tech areas.

Founded in 1986 as Arch Development Corporation by the University of Chicago and Argonne National Laboratory to commercialize university technologies, the firm originated from efforts led by Steven Lazarus, who identified the need for dedicated venture funding for spinouts. In 1992, Lazarus, along with Clint Bybee, Keith Crandell, and Robert Nelsen, transitioned it into an independent entity, Arch Venture Partners, headquartered in Chicago. This evolution allowed the firm to raise external capital independently while maintaining its roots in translating academic breakthroughs into commercial ventures, growing from initial university-backed funds to multi-billion-dollar life sciences vehicles.

ARCH's portfolio features over 130 active companies and 300 total since inception, including high-profile successes like Illumina, Juno Therapeutics (acquired), Grail (acquired), Agios Pharmaceuticals, Denali Therapeutics, Twist Bioscience, and Vir Biotechnology. These investments highlight the firm's track record in platform biotech, genomics, and immunology, with many achieving major IPOs, acquisitions, and clinical milestones, often clustering in biotech hubs like Boston, San Francisco, and Seattle.

The team comprises experienced managing directors such as co-founders Robert Nelsen and Keith Crandell, alongside specialists like Kristina Burow, Steve Gillis, and Paul Berns, supported by venture partners including George Scangos, John Maraganore, and Luciana Borio. With deep expertise in science, business development, and company-building, drawn from CEO roles at major biotechs and research institutions, the team actively partners with entrepreneurs to navigate technical risks and market challenges.